[Translation] Multiple intravenous administration of anabolic steroid injection in subjects with severe pneumonia: a randomized, double-blind, placebo-controlled phase I clinical study

评价SCAP受试者多次静脉给予不同剂量的安脑三醇注射液的安全性、耐受性及药代动力学（PK）特征，并初步探索其有效性

[Translation]

To evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of multiple intravenous administration of different doses of anabolic steroid injection to SCAP subjects, and to preliminarily explore its effectiveness

Start Date01 Apr 2023

Sponsor / Collaborator

Guangzhou Cellprotek Pharmaceutical Co., Ltd.

CTR20192127 / Active, not recruitingPhase 2

安脑三醇注射液治疗急性缺血性卒中Ⅱa期临床试验——前瞻性、多中心、随机、双盲、安慰剂平行对照研究

[Translation] Phase IIa clinical trial of anabolic steroid injection in the treatment of acute ischemic stroke: a prospective, multicenter, randomized, double-blind, placebo-controlled study

初步探索安脑三醇注射液治疗急性缺血性卒中（AIS）的有效性，并观察其对AIS患者的安全性。

[Translation]

To preliminarily explore the effectiveness of anencephalotriol injection in the treatment of acute ischemic stroke (AIS) and observe its safety in AIS patients.

Start Date10 Nov 2021

Sponsor / Collaborator

Guangzhou Cellprotek Pharmaceutical Co., Ltd.

CTR20192118 / CompletedPhase 2

安脑三醇注射液用于急性缺血性卒中的 IIa 期临床试验——前瞻性、单中心、随机、双盲、安慰剂对照研究

[Translation] Phase IIa clinical trial of anabolic steroid injection in the treatment of acute ischemic stroke: a prospective, single-center, randomized, double-blind, placebo-controlled study

在急性前循环缺血性卒中受试者中，初步探索在血管内机械取栓的基础上使用安脑三醇（YC-6）注射液的安全性和有效性。

[Translation]

In subjects with acute anterior circulation ischemic stroke, the safety and efficacy of using ycin (YC-6) injection on the basis of intravascular mechanical thrombectomy was preliminarily explored.

Start Date07 Jul 2021

Sponsor / Collaborator

Guangzhou Cellprotek Pharmaceutical Co., Ltd.

100 Clinical Results associated with Androtriol

100 Translational Medicine associated with Androtriol

100 Patents (Medical) associated with Androtriol

100 Deals associated with Androtriol

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cerebral Small Vessel Diseases	Phase 2	CN	Guangzhou Cellprotek Pharmaceutical Co., Ltd.	01 Mar 2022
Acute Ischemic Stroke	Phase 2	CN	Guangzhou Cellprotek Pharmaceutical Co., Ltd.	07 Jul 2021
Glioma	Phase 2	CN	Guangzhou Cellprotek Pharmaceutical Co., Ltd.	14 Oct 2020
Pneumonia	Phase 1	CN	Guangzhou Cellprotek Pharmaceutical Co., Ltd.	01 Apr 2023
Cerebral Hemorrhage	IND Approval	CN	Guangzhou Cellprotek Pharmaceutical Co., Ltd.	27 Nov 2023
Brain Edema	Preclinical	CN	Guangzhou Cellprotek Pharmaceutical Co., Ltd.	13 Aug 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis